Vaxcyte Inc PCVX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/29/24 EDT
61.03UNCH (UNCH)
Volume
26,826
Close
61.03UNCH (UNCH)
Volume
473,779
52 week range
42.98 - 82.04
Loading...
  • Open61.07
  • Day High62.28
  • Day Low60.72
  • Prev Close61.03
  • 52 Week High82.04
  • 52 Week High Date02/28/24
  • 52 Week Low42.98
  • 52 Week Low Date05/01/23

Key Stats

  • Market Cap6.638B
  • Shares Out108.76M
  • 10 Day Average Volume0.83M
  • Dividend-
  • Dividend Yield-
  • Beta0.93
  • YTD % Change-2.82

KEY STATS

  • Open61.07
  • Day High62.28
  • Day Low60.72
  • Prev Close61.03
  • 52 Week High82.04
  • 52 Week High Date02/28/24
  • 52 Week Low42.98
  • 52 Week Low Date05/01/23
  • Market Cap6.638B
  • Shares Out108.76M
  • 10 Day Average Volume0.83M
  • Dividend-
  • Dividend Yield-
  • Beta0.93
  • YTD % Change-2.82

RATIOS/PROFITABILITY

  • EPS (TTM)-4.07
  • P/E (TTM)-14.98
  • Fwd P/E (NTM)-13.03
  • EBITDA (TTM)-389.885M
  • ROE (TTM)-36.67%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vaxcyte Inc

Profile

MORE
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also...
Carlos Paya M.D., Ph.D.
Independent Chairman of the Board
Grant Pickering
Chief Executive Officer, Co-Founder, Director
Andrew Guggenhime
President, Chief Financial Officer
James Wassil
Chief Operating Officer, Executive Vice President
Address
825 INDUSTRIAL ROAD, STE. 300
San Carlos, CA
94070
United States

Top Peers

SYMBOLLASTCHG%CHG
VKTX
Viking Therapeutics Inc
75.42UNCHUNCH
CYTK
Cytokinetics Inc
62.53UNCHUNCH
RVMD
Revolution Medicines Inc
37.11UNCHUNCH
CERE
Cerevel Therapeutics Holdings Inc
42.75UNCHUNCH
BBIO
BridgeBio Pharma Inc
25.47UNCHUNCH